|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||44.52 - 44.92|
|52 Week Range||38.61 - 51.17|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.58%|
The following is original research by ARK's Genomic Revolution Analyst, Manisha Samy . Genome-Editing During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in ...
Prime Minister May Looks to Bolster the Sector Earlier this year, Prime Minister Theresa May earmarked life sciences as one of five areas critical to the UK’s economic growth and commissioned a proposal on how to bolster the sector, especially as the ...
Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.
Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we'll look at its ...
Trump pledged to initiate a bidding process for drug cost that shed roughly $24.6 billion in 20 minutes from the nine biggest pharmaceutical companies by market cap.
While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).